Trade Show

AMP 2018 Corporate Workshop

NeuMoDx™ Molecular, a QIAGEN company presented the NeuMoDx™ 288 Molecular System at Association for Molecular Pathology in 2018. Christen Griego-Fullbright and Dr. Stephen Young were keynote speakers at our workshop. They were able to work with our system firsthand and present their experiences using our system. If you would like to view the full presentation please fill out the form below.

    CVS 2019 Trade Show

    If you’re in Savannah, Georgia this week for the American Society for Microbiology’s Clinical Virology Symposium, NeuMoDx™ teammate Jason has a message for you! Stop by booth #547 now through Wednesday, May 8 at #ASMCVS – we can’t wait to show you the future of molecular diagnostics.

    NeuMoDx™ System Launches at ESCV

    The NeuMoDx™ 96 and 288 Molecular Systems were formally launched at the QIAGEN booth at ESCV 2018 in Athens, Greece, provided robust feedback from clinicians, researchers, lab workers and industry members.


    Interview with Jeff Williams

    NeuMoDx™ Molecular was recently at ECCMID displaying our NeuMoDx™ Molecular 288 System. Our system is capable of automated extraction and isolation of nucleic acids from multiple specimen types, as well as the automated amplification and detection of target nucleic acid sequences by fluorescence-based PCR.

    Dr. Steven Young Video Testimonial

    NeuMoDx™ platforms are built to handle large volumes of sample in an automated fashion, integrating the entire molecular diagnostic process from sample to result. Dr. Steven Young, Director of Research and Clinical Trials at TriCore Reference Laboratories, has been working with NeuMoDx™ on an invitro diagnostics test approved by the FDA, using our instrumentation.

    Technology & Workflow

    NeuMoDx™ 288 Molecular System Technology & Workflow

    The NeuMoDx™ 288 Molecular System is designed for the automated extraction and isolation of nucleic acids, as well as the automated amplification and detection of target nucleic acid sequences by fluorescence-based PCR.


    We are excited to announce that QIAGEN has acquired all shares of NeuMoDx Molecular, Inc. The addition of NeuMoDx’s medium- and high-throughput molecular systems further expands QIAGEN’s portfolio of molecular diagnostics instruments, bolstering our leadership in automated molecular testing. We are proud to welcome NeuMoDx to our family of PCR solutions that make improvements in life possible.

    To learn more, click here.